Ron Cooper

Ron Cooper is the chief executive officer of enGene Holdings Inc. Previously, he served as the president and chief executive officer of Albireo Pharma, Inc., from July 2015 and a member of its board of directors from November 2016, both until its acquisition by Ipsen Biopharmaceuticals, Inc. in March 2023. As Albireo’s first president and chief executive officer, Ron took the company public in 2016 and advanced a deep pipeline through multiple late-stage clinical trials. Prior to joining Albireo, he spent more than 25 years at Bristol Myers Squibb, working in five different countries and holding positions of increasing responsibility in sales, marketing, and general management, culminating in his role as president of Europe, where he was responsible for over 30 countries. While at BMS, Ron played a leadership role in several product successes, including Abilify®, Avapro®, Atripla®, Eliquis®, Orencia®, Pravachol®, Plavix®, Reyataz®, Sustiva®, Sprycel®, and Yervoy®. Ron has successfully completed more than a dozen business development deals and is currently a member of the Board of Directors of C4 Therapeutics. He is a graduate of St. Francis Xavier University in Canada.